Pharmacoeconomic evaluation models for hepatitis C therapies: a systematic review_Chinese Journal of Evidence-Based Medicine

Authors：

MENG Rui ,  LI Hongchao

School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, P.R.China;

Corresponding author：

LI Hongchao, Email: lihongchao@cpu.edu.cn

Keywords：

Hepatitis C treatment; Economic evaluation model; Direct-acting antiviral drugs (DAAs); Systematic review

DOI：

10.7507/1672-2531.202001015

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objectives To systematically review the methods of pharmacoeconomic evaluation model for hepatitis C therapies and to identify shortcomings of the existing modeling research by comparing the model structure, hypothesis and methodological differences, and to provide suggestions for the construction of high-quality hepatitis C pharmacoeconomic evaluation models.Methods PubMed, EMbase, The Cochrane Library, CNKI and WanFang Data databases were electronically searched to collect relevant literatures on the pharmacoeconomic evaluation models for hepatitis C therapies from August 2014 to August 2019. Two reviewers independently screened literature, extracted data, and evaluated the quality of the included studies. Then, the data related to the model structure, methods, and assumptions were compared and summarized.Results Most of the 46 studies that finally included used similar modeling methods. Ignoring different modeling elements would cause overestimation or underestimation of the value of hepatitis C therapies. Model structure of all studies were similar and key parameters were from the same source. Forty-five studies measured the cost of drugs and medical cost of health status. All studies used quality-adjusted life years as the outcome and reported incremental cost-effectiveness ratio. Thirty studies conducted one-way sensitivity analysis and probability sensitivity analysis.Conclusions The included studies share similar methodological designs and have high quality in general. However, there are some differences and deficiencies in research perspective, model types, model assumptions and model verification. Future pharmacoeconomic evaluation model of hepatitis C therapies should report the results of the whole society, establish dynamic model to consider the impact of transmission, make half-cycle correction for long periods, consider the recurrence after cure, model liver transplantation, and verify the model.

Citation： MENG Rui, LI Hongchao. Pharmacoeconomic evaluation models for hepatitis C therapies: a systematic review. Chinese Journal of Evidence-Based Medicine, 2020, 20(9): 1027-1037. doi: 10.7507/1672-2531.202001015 Copy

1.	Stepanova M, Younossi ZM. Economic burden of hepatitis C infection. Clin Liver Dis, 2017, 21(3): 579-594.
2.	Husereau D, Drummond M, Petrou S, <italic>et al</italic>. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health, 2013, 16(2): 231-250.
3.	Husereau D, Drummond M, Petrou S, <italic>et al</italic>. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Int J Technol Assess Health Care, 2013, 29(2): 117-122.
4.	Chen P, Ma A, Liu Q. Cost-Effectiveness of elbasvir/grazoprevir versus daclatasvir plus asunaprevir in patients with chronic hepatitis C virus genotype 1b infection in China. Clin Drug Investig, 2018, 38(11): 1031-1039.
5.	Rolli FR, Ruggeri M, Kheiraoui F, <italic>et al</italic>. Economic evaluation of Zepatier for the management of HCV in the Italian scenario. Eur J Health Econ, 2018, 19(9): 1365-1374.
6.	Lu Y, Jin X, Duan CA, <italic>et al</italic>. Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China. PLoS One, 2018, 13(4): e0195117.
7.	Rattanavipapong W, Anothaisintawee T, Teerawattananon Y. Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis. PLoS One, 2018, 13(2): e0193112.
8.	Liu Y, Wang Z, Tobe RG, <italic>et al</italic>. Cost effectiveness of daclatasvir plus asunaprevir therapy for Chinese patients with chronic hepatitis C virus genotype 1b. Clin Drug Investig, 2018, 38(5): 427-437.
9.	Wisløff T, White R, Dalgard O, <italic>et al</italic>. Economic evaluation of direct-acting antivirals for hepatitis C in Norway. Pharmacoeconomics, 2018, 36(5): 591-601.
10.	Corman S, Elbasha EH, Michalopoulos SN, <italic>et al</italic>. Cost-utility of elbasvir/grazoprevir in patients with chronic hepatitis C genotype 1 infection. Value Health, 2017, 20(8): 1110-1120.
11.	Mattingly TJ 2nd, Slejko JF, Mullins CD. Hepatitis C treatment regimens are cost-effective: but compared with what? Ann Pharmacother, 2017, 51(11): 961-969.
12.	Ward T, Webster S, Mishina S, <italic>et al</italic>. Assessing the budget impact and economic outcomes of the introduction of daclatasvir + asunaprevir and sofosbuvir/ledipasvir for the treatment of chronic hepatitis C virus infection in Japan. Value Health Reg Issues, 2017, 12: 1-6.
13.	Lo AO, Chan HL, Wong VW, <italic>et al</italic>. Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong. J Gastroenterol Hepatol, 2017, 32(5): 1071-1078.
14.	Restelli U, Alberti A, Lazzarin A, <italic>et al</italic>. Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy. Eur J Health Econ, 2018, 19(1): 37-44.
15.	Elbasha EH, Robertson MN, Nwankwo C. The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States. Aliment Pharmacol Ther, 2017, 45(3): 455-467.
16.	Igarashi A, Tang W, Guerra I, <italic>et al</italic>. Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan. Curr Med Res Opin, 2017, 33(1): 11-21.
17.	Igarashi A, Tang W, Cure S, <italic>et al</italic>. Cost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan. Curr Med Res Opin, 2017, 33(1): 1-10.
18.	Gimeno-Ballester V, Mar J, O'Leary A, <italic>et al</italic>. Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients. Expert Rev Gastroenterol Hepatol, 2017, 11(1): 85-93.
19.	Chung W, Kim KA, Jang ES, <italic>et al</italic>. Cost-effectiveness of sofosbuvir plus ribavirin therapy for hepatitis C virus genotype 2 infection in South Korea. J Gastroenterol Hepatol, 2019, 34(4): 776-783.
20.	Ji D, Chen GF, Wang C, <italic>et al</italic>. Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients. Hepatol Int, 2016, 10(5): 789-798.
21.	Virabhak S, Yasui K, Yamazaki K, <italic>et al</italic>. Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan. J Med Econ, 2016, 19(12): 1144-1156.
22.	Chen GF, Wei L, Chen J, <italic>et al</italic>. Will sofosbuvir/ledipasvir (harvoni) be cost-effective and affordable for Chinese patients infected with hepatitis C virus? An economic analysis using real-world data. PLoS One, 2016, 11(6): e0155934.
23.	Deuffic-Burban S, Obach D, Canva V, <italic>et al</italic>. Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case. J Viral Hepat, 2016, 23(10): 767-779.
24.	Zhao YJ, Khoo AL, Lin L, <italic>et al</italic>. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C. J Gastroenterol Hepatol, 2016, 31(9): 1628-1637.
25.	Johnson SJ, Parisé H, Virabhak S, <italic>et al</italic>. Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection. J Med Econ, 2016, 19(10): 983-994.
26.	Saab S, Parisé H, Virabhak S, <italic>et al</italic>. Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US. J Med Econ, 2016, 19(8): 795-805.
27.	Saab S, Gonzalez YS, Huber C, <italic>et al</italic>. Cost-effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir+ribavirin for US post-liver transplant recurrent genotype 1 HCV. Liver Int, 2016, 36(4): 515-521.
28.	Fraser I, Burger J, Lubbe M, <italic>et al</italic>. Cost-effectiveness modelling of sofosbuvir-containing regimens for chronic genotype 5 hepatitis C virus infection in South Africa. Pharmacoeconomics, 2016, 34(4): 403-417.
29.	McEwan P, Bennett H, Ward T, <italic>et al</italic>. The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK. Eur J Gastroenterol Hepatol, 2016, 28(2): 173-180.
30.	Vargas CL, Espinoza MA, Giglio A, <italic>et al</italic>. Cost Effectiveness of daclatasvir/asunaprevir versus peginterferon/ribavirin and protease inhibitors for the treatment of hepatitis C genotype 1b naïve patients in Chile. PLoS One, 2015, 10(11): e0141660.
31.	Chidi AP, Rogal S, Bryce CL, <italic>et al</italic>. Cost-effectiveness of new antiviral regimens for treatment-naïve U. S. veterans with hepatitis C. Hepatology, 2016, 63(2): 428-436.
32.	Gimeno-Ballester V, Mar J, San Miguel R. Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C. Expert Rev Pharmacoecon Outcomes Res, 2016, 16(2): 285-294.
33.	Moshyk A, Martel MJ, Tahami Monfared AA, <italic>et al</italic>. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada. J Med Econ, 2016, 19(2): 181-192.
34.	Zhang S, Bastian ND, Griffin PM. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US. BMC Gastroenterol, 2015, 15: 98.
35.	Cure S, Guerra I, Dusheiko G. Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients. J Viral Hepat, 2015, 22(11): 882-889.
36.	Westerhout K, Treur M, Mehnert A, <italic>et al</italic>. A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service. J Med Econ, 2015, 18(10): 838-849.
37.	Cure S, Guerra I, Cammà C, <italic>et al</italic>. Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy. J Med Econ, 2015, 18(9): 678-690.
38.	Linas BP, Barter DM, Morgan JR, <italic>et al</italic>. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med, 2015, 162(9): 619-629.
39.	Najafzadeh M, Andersson K, Shrank WH, <italic>et al</italic>. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med, 2015, 162(6): 407-419.
40.	Kuwabara H, Westerhout K, Treur M, <italic>et al</italic>. Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan. J Med Econ, 2015, 18(7): 502-511.
41.	Younossi ZM, Park H, Saab S, <italic>et al</italic>. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther, 2015, 41(6): 544-563.
42.	San Miguel R, Gimeno-Ballester V, Blázquez A, <italic>et al</italic>. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut, 2015, 64(8): 1277-1288.
43.	Liu S, Watcha D, Holodniy M, <italic>et al</italic>. Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U. S. incarcerated populations: a cost-effectiveness analysis. Ann Intern Med, 2014, 161(8): 546-553.
44.	Petta S, Cabibbo G, Enea M, <italic>et al</italic>. Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Dig Liver Dis, 2014, 46(10): 936-942.
45.	陈平钰, 李洪超, 马爱霞. 艾尔巴韦/格拉瑞韦片治疗基因 1b 型慢性丙型肝炎的经济学评价. 中国循证医学杂志, 2018, 18(12): 1352-1358.
46.	陈平钰, 谢青. 艾尔巴韦格拉瑞韦与索磷布韦维帕他韦治疗丙型肝炎的成本-效果分析. 中国药物经济学, 2019, 14(7): 14-18+26.
47.	陈海, 陈洁玲, 陆志刚, 等. 基于 Markov 模型建立慢性丙肝治疗的药物经济学模型. 中国卫生统计, 2016, 33(3): 370-373+378.
48.	付露阳, 马爱霞. 盐酸达拉他韦联合阿舒瑞韦治疗慢性丙型肝炎的经济学评价. 中国药物经济学, 2018, 13(6): 5-9.
49.	杨馥宁, 贺小宁, 吴晶. 基于 Markov 模型对新型抗病毒药物治疗基因 1b 型慢性丙型肝炎的药物经济学评价. 中国药学杂志, 2019, 54(15): 1276-1284.
50.	高丽, 杨绍敏. HCV 基因分型进展及临床意义. 传染病信息, 2013, 26(2): 122-125.
51.	Chhatwal J, He T, Lopez-Olivo MA. Systematic review of modelling approaches for the cost effectiveness of hepatitis C treatment with direct-acting antivirals. Pharmacoeconomics, 2016, 34(6): 551-567.
52.	赵可新, 李岑, 张睿, 等. 模型研究方法在药物经济学中的应用概述. 中国药师, 2015, 18(9): 1561-1564.
53.	Chhatwal J, Chen Q, Aggarwal R. Estimation of hepatitis C disease burden and budget impact of treatment using health economic modeling. Infect Dis Clin North Am, 2018, 32(2): 461-480.
54.	Caro JJ, Briggs AH, Siebert U, <italic>et al</italic>. Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1. Value Health, 2012, 15(6): 796-803.
55.	刘洁, 顾海. 药品不良反应成本测算研究. 卫生经济研究, 2007, (2): 18-19.
56.	赵亚栋, 屠爱霞, 王晓蕊, 等. 甘肃省2004-2018年丙型肝炎流行特征. 中华疾病控制杂志, 2019, 23(8): 922-926, 931.
57.	蒙明虑, 熊国林, 黄斯梅, 等. 广西壮族自治区16岁以上高中生丙型肝炎病毒感染状况调查. 中华疾病控制杂志, 2017, 21(3): 270-273.

1. Stepanova M, Younossi ZM. Economic burden of hepatitis C infection. Clin Liver Dis, 2017, 21(3): 579-594.
2. Husereau D, Drummond M, Petrou S, <italic>et al</italic>. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health, 2013, 16(2): 231-250.
3. Husereau D, Drummond M, Petrou S, <italic>et al</italic>. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Int J Technol Assess Health Care, 2013, 29(2): 117-122.
4. Chen P, Ma A, Liu Q. Cost-Effectiveness of elbasvir/grazoprevir versus daclatasvir plus asunaprevir in patients with chronic hepatitis C virus genotype 1b infection in China. Clin Drug Investig, 2018, 38(11): 1031-1039.
5. Rolli FR, Ruggeri M, Kheiraoui F, <italic>et al</italic>. Economic evaluation of Zepatier for the management of HCV in the Italian scenario. Eur J Health Econ, 2018, 19(9): 1365-1374.
6. Lu Y, Jin X, Duan CA, <italic>et al</italic>. Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China. PLoS One, 2018, 13(4): e0195117.
7. Rattanavipapong W, Anothaisintawee T, Teerawattananon Y. Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis. PLoS One, 2018, 13(2): e0193112.
8. Liu Y, Wang Z, Tobe RG, <italic>et al</italic>. Cost effectiveness of daclatasvir plus asunaprevir therapy for Chinese patients with chronic hepatitis C virus genotype 1b. Clin Drug Investig, 2018, 38(5): 427-437.
9. Wisløff T, White R, Dalgard O, <italic>et al</italic>. Economic evaluation of direct-acting antivirals for hepatitis C in Norway. Pharmacoeconomics, 2018, 36(5): 591-601.
10. Corman S, Elbasha EH, Michalopoulos SN, <italic>et al</italic>. Cost-utility of elbasvir/grazoprevir in patients with chronic hepatitis C genotype 1 infection. Value Health, 2017, 20(8): 1110-1120.
11. Mattingly TJ 2nd, Slejko JF, Mullins CD. Hepatitis C treatment regimens are cost-effective: but compared with what? Ann Pharmacother, 2017, 51(11): 961-969.
12. Ward T, Webster S, Mishina S, <italic>et al</italic>. Assessing the budget impact and economic outcomes of the introduction of daclatasvir + asunaprevir and sofosbuvir/ledipasvir for the treatment of chronic hepatitis C virus infection in Japan. Value Health Reg Issues, 2017, 12: 1-6.
13. Lo AO, Chan HL, Wong VW, <italic>et al</italic>. Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong. J Gastroenterol Hepatol, 2017, 32(5): 1071-1078.
14. Restelli U, Alberti A, Lazzarin A, <italic>et al</italic>. Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy. Eur J Health Econ, 2018, 19(1): 37-44.
15. Elbasha EH, Robertson MN, Nwankwo C. The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States. Aliment Pharmacol Ther, 2017, 45(3): 455-467.
16. Igarashi A, Tang W, Guerra I, <italic>et al</italic>. Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan. Curr Med Res Opin, 2017, 33(1): 11-21.
17. Igarashi A, Tang W, Cure S, <italic>et al</italic>. Cost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan. Curr Med Res Opin, 2017, 33(1): 1-10.
18. Gimeno-Ballester V, Mar J, O'Leary A, <italic>et al</italic>. Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients. Expert Rev Gastroenterol Hepatol, 2017, 11(1): 85-93.
19. Chung W, Kim KA, Jang ES, <italic>et al</italic>. Cost-effectiveness of sofosbuvir plus ribavirin therapy for hepatitis C virus genotype 2 infection in South Korea. J Gastroenterol Hepatol, 2019, 34(4): 776-783.
20. Ji D, Chen GF, Wang C, <italic>et al</italic>. Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients. Hepatol Int, 2016, 10(5): 789-798.
21. Virabhak S, Yasui K, Yamazaki K, <italic>et al</italic>. Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan. J Med Econ, 2016, 19(12): 1144-1156.
22. Chen GF, Wei L, Chen J, <italic>et al</italic>. Will sofosbuvir/ledipasvir (harvoni) be cost-effective and affordable for Chinese patients infected with hepatitis C virus? An economic analysis using real-world data. PLoS One, 2016, 11(6): e0155934.
23. Deuffic-Burban S, Obach D, Canva V, <italic>et al</italic>. Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case. J Viral Hepat, 2016, 23(10): 767-779.
24. Zhao YJ, Khoo AL, Lin L, <italic>et al</italic>. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C. J Gastroenterol Hepatol, 2016, 31(9): 1628-1637.
25. Johnson SJ, Parisé H, Virabhak S, <italic>et al</italic>. Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection. J Med Econ, 2016, 19(10): 983-994.
26. Saab S, Parisé H, Virabhak S, <italic>et al</italic>. Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US. J Med Econ, 2016, 19(8): 795-805.
27. Saab S, Gonzalez YS, Huber C, <italic>et al</italic>. Cost-effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir+ribavirin for US post-liver transplant recurrent genotype 1 HCV. Liver Int, 2016, 36(4): 515-521.
28. Fraser I, Burger J, Lubbe M, <italic>et al</italic>. Cost-effectiveness modelling of sofosbuvir-containing regimens for chronic genotype 5 hepatitis C virus infection in South Africa. Pharmacoeconomics, 2016, 34(4): 403-417.
29. McEwan P, Bennett H, Ward T, <italic>et al</italic>. The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK. Eur J Gastroenterol Hepatol, 2016, 28(2): 173-180.
30. Vargas CL, Espinoza MA, Giglio A, <italic>et al</italic>. Cost Effectiveness of daclatasvir/asunaprevir versus peginterferon/ribavirin and protease inhibitors for the treatment of hepatitis C genotype 1b naïve patients in Chile. PLoS One, 2015, 10(11): e0141660.
31. Chidi AP, Rogal S, Bryce CL, <italic>et al</italic>. Cost-effectiveness of new antiviral regimens for treatment-naïve U. S. veterans with hepatitis C. Hepatology, 2016, 63(2): 428-436.
32. Gimeno-Ballester V, Mar J, San Miguel R. Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C. Expert Rev Pharmacoecon Outcomes Res, 2016, 16(2): 285-294.
33. Moshyk A, Martel MJ, Tahami Monfared AA, <italic>et al</italic>. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada. J Med Econ, 2016, 19(2): 181-192.
34. Zhang S, Bastian ND, Griffin PM. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US. BMC Gastroenterol, 2015, 15: 98.
35. Cure S, Guerra I, Dusheiko G. Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients. J Viral Hepat, 2015, 22(11): 882-889.
36. Westerhout K, Treur M, Mehnert A, <italic>et al</italic>. A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service. J Med Econ, 2015, 18(10): 838-849.
37. Cure S, Guerra I, Cammà C, <italic>et al</italic>. Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy. J Med Econ, 2015, 18(9): 678-690.
38. Linas BP, Barter DM, Morgan JR, <italic>et al</italic>. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med, 2015, 162(9): 619-629.
39. Najafzadeh M, Andersson K, Shrank WH, <italic>et al</italic>. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med, 2015, 162(6): 407-419.
40. Kuwabara H, Westerhout K, Treur M, <italic>et al</italic>. Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan. J Med Econ, 2015, 18(7): 502-511.
41. Younossi ZM, Park H, Saab S, <italic>et al</italic>. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther, 2015, 41(6): 544-563.
42. San Miguel R, Gimeno-Ballester V, Blázquez A, <italic>et al</italic>. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut, 2015, 64(8): 1277-1288.
43. Liu S, Watcha D, Holodniy M, <italic>et al</italic>. Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U. S. incarcerated populations: a cost-effectiveness analysis. Ann Intern Med, 2014, 161(8): 546-553.
44. Petta S, Cabibbo G, Enea M, <italic>et al</italic>. Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Dig Liver Dis, 2014, 46(10): 936-942.
45. 陈平钰, 李洪超, 马爱霞. 艾尔巴韦/格拉瑞韦片治疗基因 1b 型慢性丙型肝炎的经济学评价. 中国循证医学杂志, 2018, 18(12): 1352-1358.
46. 陈平钰, 谢青. 艾尔巴韦格拉瑞韦与索磷布韦维帕他韦治疗丙型肝炎的成本-效果分析. 中国药物经济学, 2019, 14(7): 14-18+26.
47. 陈海, 陈洁玲, 陆志刚, 等. 基于 Markov 模型建立慢性丙肝治疗的药物经济学模型. 中国卫生统计, 2016, 33(3): 370-373+378.
48. 付露阳, 马爱霞. 盐酸达拉他韦联合阿舒瑞韦治疗慢性丙型肝炎的经济学评价. 中国药物经济学, 2018, 13(6): 5-9.
49. 杨馥宁, 贺小宁, 吴晶. 基于 Markov 模型对新型抗病毒药物治疗基因 1b 型慢性丙型肝炎的药物经济学评价. 中国药学杂志, 2019, 54(15): 1276-1284.
50. 高丽, 杨绍敏. HCV 基因分型进展及临床意义. 传染病信息, 2013, 26(2): 122-125.
51. Chhatwal J, He T, Lopez-Olivo MA. Systematic review of modelling approaches for the cost effectiveness of hepatitis C treatment with direct-acting antivirals. Pharmacoeconomics, 2016, 34(6): 551-567.
52. 赵可新, 李岑, 张睿, 等. 模型研究方法在药物经济学中的应用概述. 中国药师, 2015, 18(9): 1561-1564.
53. Chhatwal J, Chen Q, Aggarwal R. Estimation of hepatitis C disease burden and budget impact of treatment using health economic modeling. Infect Dis Clin North Am, 2018, 32(2): 461-480.
54. Caro JJ, Briggs AH, Siebert U, <italic>et al</italic>. Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1. Value Health, 2012, 15(6): 796-803.
55. 刘洁, 顾海. 药品不良反应成本测算研究. 卫生经济研究, 2007, (2): 18-19.
56. 赵亚栋, 屠爱霞, 王晓蕊, 等. 甘肃省2004-2018年丙型肝炎流行特征. 中华疾病控制杂志, 2019, 23(8): 922-926, 931.
57. 蒙明虑, 熊国林, 黄斯梅, 等. 广西壮族自治区16岁以上高中生丙型肝炎病毒感染状况调查. 中华疾病控制杂志, 2017, 21(3): 270-273.

Chinese Journal of Evidence-Based Medicine

Pharmacoeconomic evaluation models for hepatitis C therapies: a systematic review

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content